Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC1 | P33527 | 1/20 | 0.57 |
| ▸ | CACNA1C | Q13936 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3022545 | 0.87 | ABCC1 (0.74) | ABCC1CACNA1CCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL7588425 | 0.85 | ABCC1 (0.57) | ABCC1CACNA1CCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL6137184 | 0.80 | CACNA1C (0.64) | CACNA1CCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL15026362 | 0.80 | MAPT (0.54) | ABCC1CACNA1CCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL10894470 | 0.79 | CACNA1C (0.62) | CACNA1CCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL7586726 | 0.78 | CACNA1C (0.60) | CACNA1CCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL7585860 | 0.77 | ADORA3 (0.72) | CACNA1CCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL7586763 | 0.77 | CACNA1C (0.60) | CACNA1CCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL7590982 | 0.76 | CACNA1F (0.80) | CACNA1CCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL8215604 | 0.75 | ABCC1 (0.54) | ABCC1CACNA1CCYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1372657-A4 | A METHOD OF TREATING PROLIFERATIVE DISEASES USING EG5 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2005-11-09 | — | — | EP | disclosed |
| EP-1372657-A2 | A METHOD OF TREATING PROLIFERATIVE DISEASES USING EG5 INHIBITORS | Bristol-Myers Squibb Company (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20020165240-A1 | Method of treating proliferative diseases using Eg5 inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2002-11-07 | — | — | US | disclosed |
| WO-2002078639-A2 | A METHOD OF TREATING PROLIFERATIVE DISEASES USING EG5 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165240-A1 | Method of treating proliferative diseases using Eg5 inhibitors | ARF5, PDS5A, GEMIN5 | ABCC1 3467/4885CACNA1C 4688/4885CYP1A2 3956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.